Treatment of osteogenesis imperfecta with intravenous pamidronate in pediatric patients: comparison between a single-day infusion twice a year protocol with other regimens described in the literature
نویسندگان
چکیده
Conclusion Despite a lower increase in z-score in our serie, the clinical efficacy is similar to other protocols. There is a tendency towards greater gain in Z-score as the annual dosage increases. References 1. Glorieux FH, et al.: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. The New England Journal of Medicine 1998, 339:947-52. 2. Arikoski P, et al.: Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004, 34:539-46. from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14–17 September 2008
منابع مشابه
Treatment of the low bone mineral density with intravenous pamidronate in pediatric patients: review of a protocol of a single-day infusion twice a year
Materials and methods Retrospective review of patients treated with pamidronate from January 1995 to June 2006 in Sant Joan de Déu hospital (Spain). Patients:younger than 18 years that underwent treatment with the protocol for at least one year and with z-score < -2.5, fractures and z-score < -1 or documented bone pain with z-score < -1. They were classified into 4 groups: osteogenesis imperfec...
متن کاملShort-term Efficacy of Monthly Pamidronate Infusion in Patients with Osteogenesis Imperfecta
We evaluated the efficacy of a monthly infusion of pamidronate on the frequency of fractures, biochemical effects, and bone mineral density in children with osteogenesis imperfecta. Eleven patients from 0.9 to 13.8 yr of age were included in this study. The patients were administered pamidronate intravenously (30 mg/m(2)) over a 4-hr period monthly for a period ranging from 6 to 37 months. Heig...
متن کاملNew trends in the treatment of osteogenesis imperfecta type III - own experience.
INTRODUCTION Osteogenesis imperfecta (OI) is a genetic disorder caused by a mutation in the genes that encode the chains of type I collagen. Clinical manifestations include increased bone fragility and blue sclerae. OI type III is the most severe form with fractures occurring already in utero. Fracture immobilisation and orthopaedic surgery are the mainstay of treatment for patients with OI, an...
متن کاملBenefits of Pamidronate Treatment in Osteogenesis Imperfecta
Received March 9, 2004 Abstract Osteogenesis imperfecta is a hereditary disorder of connective tissues characterised by low bone mass and bone fragility. Previous studies demonstrated that cyclical pamidronate therapy is effective in increasing bone density and improving clinical outcomes in children with osteogenesis imperfecta. We report our experience in treating two children with cyclical i...
متن کاملEffect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
OBJECTIVE To assess the beneficial effect of intravenous pamidronate treatment in children with osteogenesis imperfecta (OI). STUDY DESIGN Experimental study. PLACE AND DURATION OF STUDY Endocrine Unit at the National Institute of Child Health, Karachi, Pakistan, from January 2007 to December 2011. METHODOLOGY All children diagnosed with osteogenesis imperfecta on the basis of repeated sp...
متن کامل